skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Review

(2365) Views  (457) Full article downloads

Authors: Lala M Dunbar, Derek M Tang, Robert M Manausa

Published Date March 2008 Volume 2008:4(1) Pages 235 - 244
DOI: http://dx.doi.org/10.2147/TCRM.S1843

Lala M Dunbar1, Derek M Tang2, Robert M Manausa1

1Louisiana State University Health Sciences Center, New Orleans, USA; 2Tulane University School of Medicine, USA

Abstract: Telavancin is a novel antibiotic being investigated for the treatment of serious infections caused by Gram-positive bacteria, including complicated skin and skin structure infections (cSSSI) and pneumonia. This once-daily intravenous lipoglycopeptide exerts rapid bactericidal activity via a dual mechanism of action. It is intended for use to combat infections caused by Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant and vancomycin-intermediate strains of S. aureus (MRSA and VISA, respectively). Vancomycin is the current gold standard in treating serious infections caused by Gram-positive bacteria, especially MRSA. In recent clinical trials, telavancin has shown excellent efficacy in phase II and III multinational, randomized, double-blinded studies of cSSSI. In the phase II FAST 2 study, which compared telavancin 10 mg/kg intravenously q 24 h vs standard therapy (an antistaphylococcal penicillin at 2 g IV q 6 h or vancomycin 1 gm IV q 12 h), the clinical success rate in the telavancin-treated group was 96% vs 94% in the standard therapy group. In two identical phase III trials comparing telavancin versus vancomycin at the doses of the FAST 2 study for cSSSI, the clinical cure rates were 88.3% and 87.1%, respectively. Two additional phase III clinical trials investigating telavancin for use in hospital-acquired pneumonia, caused by Gram-positive bacteria are currently ongoing. Telavancin is currently under regulatory review in both the United States and Europe for the indication of treatment of cSSSI.

Keywords: telavancin, vancomycin, MRSA








Readers of this article also read:

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Therapeutical approach to plasma homocysteine and cardiovascular risk reduction
Factors affecting therapeutic compliance: A review from the patient’s perspective
Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial
Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Optimizing prophylactic treatment of migraine: Subtypes and patient matching
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors